Anteris Technologies Global Corp. — Capital/Financing Update 2018

May 16, 2018

17.05.18

==> picture [452 x 24] intentionally omitted <==

ASX ANNOUNCEMENT

ASX Market Announcements Australian Securities Exchange Limited 10[th] Floor, 20 Bond Street SYDNEY NSW 2000

Admedus Limited (ASX:AHZ)

ADMEDUS SECURES DISTRIBUTION AGREEMENT WITH CARDIVA

Admedus Limited (ASX:AHZ) is pleased to announce it has signed an exclusive distribution agreement with leading healthcare group, Cardiva, to market and supply its clinicallysuperior ADAPT® tissue products in Spain and Portugal.

Under the agreement, Cardiva will initially distribute Admedus’ flagship ADAPT® tissue product CardioCel®, a non-calcifying, non-toxic bio-scaffold used to treat congenital heart defect and disease.

Additional ADAPT® products, VascuCel® and CardioCel 3D®, will be added to the Cardiva distribution portfolio later in the year.

With a team of more than 120 professionals, Cardiva has been a leading company in the Spanish and Portuguese health system for nearly three decades - providing physicians access to a wide range of innovative devices in the areas of interventional cardiology, vascular and cardiac surgery and pain management.

Admedus Chief Operating Officer, David St Denis welcomed the new agreement,

“Through this partnership with Cardiva, Admedus is thrilled to offer our clinically superior ADAPT® products to patients in Spain and Portugal - one of the five largest markets in Europe.”

“Cardiva is a proven and highly-regarded healthcare company and this agreement represents another important milestone in Adremedus’ evolution as a leading medical technology company.”

“With first orders due this month, we anticipate demand in this region to grow steadily as more surgeons are introduced to the unique clinical and health benefits of our ADAPT® technology,” he said.

Cardiva Director, Carlos Ibares Sanz, also welcomed today’s announcement,

“Cardiva is excited to partner with Admedus, whose products and technology are at the forefront of cardiovascular science and bio-tissue engineering. This is an excellent opportunity for both Companies to reinforce their position as demonstrated leaders in

Admedus Limited ABN 35 088 221 078

Registered Office Level 9 301 Coronation Drive Milton QLD 4064

Customer Service T 1300 550 310 F 1300 880 398

International T: +61 8 9266 0100 F: +61 8 9266 0199

E: info@admedus.com W: www.admedus.com

Brisbane • Minneapolis Zurich • Singapore

==> picture [452 x 24] intentionally omitted <==

cardiovascular health and we look forward to introducing their unique ADAPT® products to the Spanish and Portuguese market.”

The distribution agreement is effectively immediately.

ENDS

About Admedus Limited

Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Website: www.admedus.com Facebook: www.facebook.com/Admedus Twitter: @Admedus

For more information, please contact:

Admedus Limited

Barbara Ferres Communications Manager +61 7 3152 3216 communications@admedus.com

Admedus Limited ABN 35 088 221 078

Customer Service

T 1300 550 310 F 1300 880 398 International T: +61 8 9266 0100 F: +61 8 9266 0199

E: info@admedus.com W: www.admedus.com Brisbane • Minneapolis Zurich • Singapore

Registered Office Level 9 301 Coronation Drive Milton QLD 4064